Merck reported positive Phase 3 results for sacituzumab tirumotecan in advanced endometrial cancer, meeting dual primary endpoints. The EU also recommended approval for KEYTRUDA plus Padcev as perioperative treatment for bladder cancer. However, Gardasil sales are plunging due to weak China demand and inventory issues, clouding the vaccine outlook. Despite this, Merck stock has risen on strong cancer data and is considered a low-risk buy.